In contrast to previous studies, when comparing the ShotBlocker® and Buzzy® during insulin administration in children aged six to twelve diagnosed with Type 1 Diabetes Mellitus, the ShotBlocker® obtained the lowest scores in both pain and anxiety assessment, based on self-report, caregiver, and researcher evaluations(28). This evidence concerns the gene INS and type 1 diabetes mellitus.